Quarterly report · Q3
9987.TEDINET S100Q7UC
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.76T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.69T | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥24.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥12.8bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥27.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥27.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥18.7bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥18.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥18.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥13.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.29T | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥891.5bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥412.7bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥419.7bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥169.8bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥208.46 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.02 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.25 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 31.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.5% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥170.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥30.1bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥140.5bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.5bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥65.6bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥65.6bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10m |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.69T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.65T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥38.8bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥20.3bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥34.0bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥25.8bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.96T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.76T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥205.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥136.4bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥29.5bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥107.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.8bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥66.8bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥66.8bn |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥20m |
| jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥1.62T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥1.58T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥40.1bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥7.0bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥34.0bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥9.5bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥24.5bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥1.86T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥1.69T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥171.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥12.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 354
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |